Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of allisartan isoproxil + indapamide sustained-release in primary hypertension inadequately controlled by allisartan isoproxil alone
CTR20220036Phase 3Active
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of allisartan isoproxil, indapamide in essential hypertension, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Started May 2022; status: active.
02
Drugs
allisartan isoproxilindapamide
03
Conditions
essential hypertension
Beyond the preview
Go deeper on CTR20220036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220036.